Minnesota Reports $1.34 Billion in 340B Revenue
Minnesota’s second year of 340B reporting shows that Covered Entities generated at least $1.34 billion in net 340B revenue in…
Browsing: Drug Pricing
Aimed Alliance Urges Maryland PDAB to Protect Patient Access in UPL Deliberations
Aimed Alliance sent letters to the Maryland PDAB urging it to proceed cautiously with setting a UPL for Jardiance and…
GLOBE Model Expected to Have Minimal Impact on Part B OOP Costs
A new analysis published by Avalere Health found that the proposed GLOBE (Global Benchmark for Efficient Drug Pricing) Model would have…
New Report – International Reference Pricing: Lessons Learned from Abroad
For decades, rising costs of health care, health insurance, and prescription drugs have been a major concern for American consumers, caregivers,…
Aimed Alliance Urges Reconsideration of VA PDAB Bill
Aimed Alliance recently sent a letter urging the Virginia House Labor and Commerce Committee to reconsider House Bill 483, which…
Aimed Alliance Publishes Updated 2025 PDAB Resources
Aimed Alliance is pleased to share two new resources on prescription drug affordability boards (PDABs). PDABs are established at the…
Aimed Alliance Publishes New Resource on the USTR and MFN
Aimed Alliance has released a new fact sheet explaining the role of the U.S. Trade Representative (USTR) in shaping international…
CMS Launches GENEROUS Model to Lower Medicaid Drug Costs and Expand Access
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) announced a new drug payment initiative aimed at addressing…
Aimed Alliance Releases New Explainer on 340B Program
On October 22, Aimed Alliance published a new resource on the 340B Drug Pricing Program (340B Program). The 340B program…
Colorado Sets Nation’s First UPL, Raising Patient Safeguards Concerns
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…